NASDAQ:CLCY

Health·NASDAQ:CLCY·News·Oncology·Pharmaceuticals

Celcuity Rises Ahead of ASCO Update With FDA Deadline Pressing

Celcuity shares rose $2.14 to $132.88 late Friday on volume of 1.42 million. The company will present full VIKTORIA-1 breast cancer trial results June 2 at ASCO and expects an FDA decision on gedatolisib by July 17. CEO Brian Sullivan is scheduled to speak at Jefferies on June 4 and Goldman Sachs on June 10. Celcuity reported a Q1 net loss of $52.8 million.

May 30, 2026

Shaver Shop Group Offers 11% Dividend Yield with Growth Potential on ASX
May 29, 2026, 8:11 PM EDT. Shaver Shop Group Ltd (ASX: SSG) is emerging as a compelling dividend stock with a 11.1% trailing grossed-up dividend yield, including franking credits. The retailer has a history of stable and growing payouts since 2017, with no dividend cuts. The FY25 dividend was 10.3 cents per share, and FY26 is expected to maintain similar levels. Trading below 12 times FY26 estimated earnings, Shaver Shop shows earnings growth potential with projections of EPS rising from 11.6 cents in FY26 to 14.1 cents in FY28. Growth drivers include store expansion, improved margins, online sales, exclusive brand products, and diversification into oral health and beauty categories. Investors should weigh these positives against broader market and company risks.